Boehringer Reports Positive Phase II Data of Cancer Drug
Posted on: Monday, 28 April 2008, 09:00 CDT
Boehringer Ingelheim has announced results from a Phase II study in patients with advanced, relapsed non-small cell lung cancer, which showed that, monotherapy treatment with the triple angiokinase inhibitor BIBF 1120 offers promising efficacy and is well tolerated.
This Phase II study investigated the efficacy of BIBF 1120 in 73 patients with an ECOG score of 0-2 with locally advanced or metastatic non-small cell lung cancer (NSCLC) (stage 11B/IV).
Of particular note were results from a subset of 57 patients with 'good disease state' (ECOG performance status of zero or one): these patients experienced longer overall survival (median overall survival was 9.5 months), longer progression-free survival (PFS; median PFS was 2.9 months) and a higher stable disease rate of 59% compared with the overall study population.
Andreas Barner, vice chairman of the board of managing directors at Boehringer Ingelheim, said: "These new BIBF 1120 Phase II data, coupled with evidence from previous studies that show BIBF 1120 is well tolerated in combination with standard lung cancer treatments, gives us great confidence in moving forward with further investigations of BIBF 1120 in lung cancer."
Source: Datamonitor
Related Articles
- ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
- ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
- Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients
- Aradigm Announces Data Showing No Occurrence of Primary Lung Cancer in Patients Treated With AERx(R) Insulin Diabetes Management System (iDMS)
- Plethora Completes Patient Recruitment in Phase IIb Dysmenorrhoea Study
- Oncolytics Completes Patient Enrollment in Phase Ia/Ib Cancer Trial
- Merck's Lung Cancer Drug Performs Well in Phase II Trial
- Another Step on the Journey to Hope for MDS Patients: New Study Demonstrates Survival Benefit in Patients With MDS (Myelodysplastic Syndromes)
- GammaCan Reports on Patient Enrollment in Phase II Clinical Trial; Company Pursues Toxicity and Efficacy Study of GCAN 101, Proprietary IVIg Therapy for Metastatic Cancers
- ImClone Systems Commences Patient Treatment in U.S. Phase I Clinical Trial Of IMC-1121B
 |
 |
User Comments (0)
RSS Feeds